



# Grŵp Strategaeth Meddyginiaethau Cymru Gyfan All Wales Medicines Strategy Group

Meeting to commence at 9.30 am on Wednesday, 15<sup>th</sup> July 2020  
(via Zoom)

## AGENDA

- |  | Enclosure                  |
|--|----------------------------|
| 1. Welcome and introduction  |                            |
| 2. Apologies   |                            |
| 3. Declarations of interest  |                            |
| 4. Minutes of the previous meeting   | 1/AWMSG/0720               |
| 5. Chairman's verbal report  |                            |
| 6. National Prescribing Indicator Report (Q3) <b>for information</b>   | 2/AWMSG/0720               |
| 7. All Wales Prescribing Guidelines for Asthma <b>for endorsement as interim guidance in Wales</b>   | 3/AWMSG/0720               |
| 8. SCHE Collaborative Research – Liothyronine <b>for information and not available on the AWMSG website as 'academic in confidence'</b>  | 4/AWMSG/0720               |
| 9. Appraisal 1: Full submission<br>Cariprazine (Reagila <sup>®</sup> ) for the treatment of schizophrenia in adult patients.   | 5/AWMSG/0720<br>Enclosures |
| 10. Appraisal 2: Full submission (orphan medicine)<br>Hydroxycarbamide (Xromi <sup>®</sup> ) for the prevention of vaso-occlusive complications of sickle cell disease in patients over 2 years of age | 6/AWMSG/0720<br>Enclosures |

**To protect commercial confidentiality the following appraisal will be held in private and all observers will be asked to leave the meeting**

- |  |                            |
|--|----------------------------|
| 11. Appraisal 3: Limited submission (Patient Access Scheme)<br>Belimumab (Benlysta <sup>®</sup> ) as add-on therapy in patients aged 5 years to < 18 years old with active, autoantibody-positive systemic lupus erythematosus with a high degree of disease activity (e.g. positive anti-dsDNA and low complement) despite standard therapy | 7/AWMSG/0720<br>Enclosures |
|--|----------------------------|

**The outcome of the appraisal/s will be uploaded to the AWMSG website after the meeting. The applicant company will have ten working days to accept the decision or lodge a request for a review which should be sent to the AWMSG Chair via AW TTC. AWMSG's recommendation/s will be forwarded to Welsh Government for ratification following acceptance of the outcome by the applicant company or after the ten day deadline has expired – whichever is sooner. Welsh Government will take into account the AWMSG recommendation when making the final decision on the availability of the medicine in NHS Wales.**

Date of next meeting: Tuesday 15<sup>th</sup> September 2020 commencing 9.30 am